← All trials
NCT05287503
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2022
- Primary completion
- Jan 30, 2024
- Completion date
- Jun 15, 2024
- First posted
- Mar 18, 2022
- Last posted
- Mar 18, 2022
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaLead sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOverall official - principal investigator
- IRCCS National Neurological Institute C. Mondino FoundationCollaborator
- University of Campania Luigi VanvitelliCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.